Key Highlights

● Gilead Sciences closed at $156.19 on October 16, trading below the analyst target.

● The consensus 12-month price target is $159.85, implying about 2.3% upside.

● Analysts are split 22 Buy, 5 Hold, and 1 Sell on the stock.

● Targets range from $126 to $180 across 28 analysts.

Gilead Sciences, Inc. (NASDAQ:GILD) closed at $156.19 on October 16, 2026. The average analyst 12-month price target is $159.85, which is 2.3 % above that close, according to market data. Gilead Sciences is a member of the S&P 500. Large pharmaceutical shares, including Gilead, have been trading at or near record highs according to market data, which has narrowed the gap between price and targets.

What Is the Latest Analyst Price Target?

The consensus average target is $159.85, the median is $165, the high is $180 and the low is $126, drawn from 28 analysts. Data date: October 16, 2026. The implied move from the latest price is 2.3 % upside, although targets are forecasts rather than guarantees.

What Are Analysts Saying?

The ratings split is 22 Buy, 5 Hold, 1 Sell, giving a consensus rating of Buy. Listed actions include Leerink Partners maintaining Hold and trimming its target from $130 to $129 (October 15, 2026), Wells Fargo reiterating Buy at $165 (14 October), BMO Capital maintaining Buy at $174 and Citi maintaining Buy at $165 (12 October), and Bank of America raising its target from $162 to $168 (12 October). Around five weeks earlier, JPMorgan raised its target to $170 from $160 and HSBC to $175 from $155.

What Could Help the Stock Reach the Price Target?

Supportive factors could include growth for lenacapavir, with an agreement with the Pan American Health Organization and expanded licensing covering an investigational once-yearly formulation. A collaboration with Vir Biotechnology on T-cell engager candidates adds to the pipeline. If the consensus proves accurate, the shares could move towards the average target over the next twelve months, but this depends on earnings delivery and market conditions.

What Could Prevent the Stock Reaching the Target?

The mean target is only modestly above the price, and the low target of $126 is well below it, which suggests much of the recent optimism may already be reflected. Pricing pressure, policy changes, competition in HIV treatment and prevention, and pipeline setbacks are risks. Analyst targets are revised frequently and can be wrong, and the figures above may differ between data providers.

What Should Investors Watch Next?

Gilead plans to report third-quarter 2026 results and guidance on October 29, 2026. Investors may watch lenacapavir uptake, any guidance revision and subsequent changes to broker targets.

Mostly Priced In Already

The consensus target of $159.85 for Gilead Sciences suggests 2.3 % upside from the $156.19 close on October 16, 2026, based on 28 analysts.